Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 23274955)

1.

Agalsidase benefits renal histology in young patients with Fabry disease.

Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E.

J Am Soc Nephrol. 2013 Jan;24(1):137-48. doi: 10.1681/ASN.2012030316.

2.

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.

Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska A.

Genet Med. 2009 Apr;11(4):256-64. doi: 10.1097/GIM.0b013e3181981d82.

PMID:
19265719
3.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
4.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
5.

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P.

Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16.

PMID:
23680766
6.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.

7.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE.

Orphanet J Rare Dis. 2011 Oct 31;6:69. doi: 10.1186/1750-1172-6-69.

8.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

9.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
10.

Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.

Hirashio S, Taguchi T, Naito T, Maki K, Ogata S, Taniyama K, Taniguchi Y, Yorioka N.

Clin Nephrol. 2009 May;71(5):550-6.

PMID:
19473616
11.

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M.

J Inherit Metab Dis. 2003;26(7):617-27.

PMID:
14707510
12.

Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.

Kampmann C, Linhart A, Devereux RB, Schiffmann R.

Clin Ther. 2009 Sep;31(9):1966-76. doi: 10.1016/j.clinthera.2009.09.008.

PMID:
19843486
13.

[Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].

Thomaidis T, Relle M, Reinke J, Beck M, Schwarting A.

Med Klin (Munich). 2009 Sep 15;104(9):699-703. doi: 10.1007/s00063-009-1152-1. Epub 2009 Sep 23. Review. German.

PMID:
19779674
14.

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R.

J Clin Pharmacol. 2007 Oct;47(10):1222-30. Epub 2007 Aug 13.

PMID:
17698592
15.

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP; International Fabry Disease Study Group.

Am J Hum Genet. 2004 Jul;75(1):65-74. Epub 2004 May 20.

16.

Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.

Kisinovsky I, Cáceres G, Coronel C, Reisin R.

Medicina (B Aires). 2013;73(1):31-4.

17.
18.

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M; FOS Investigators.

Clin J Am Soc Nephrol. 2012 Jan;7(1):60-9. doi: 10.2215/CJN.03130411.

19.

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Maródi L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; Fabry Registry.

Nephrol Dial Transplant. 2012 Mar;27(3):1042-9. doi: 10.1093/ndt/gfr420. Epub 2011 Jul 29.

20.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Nascimento P, Pastores GM.

Cochrane Database Syst Rev. 2013 Feb 28;2:CD006663. doi: 10.1002/14651858.CD006663.pub3. Review.

PMID:
23450571
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk